Efficacy and safety of inclisiran as monotherapy in patients with primary hypercholesterolemia not receiving lipid-lowering therapy. ClinicalTrials.gov. Updated July 11, 2024. Accessed August 30 ...

We conducted a phase 2, multicenter, double-blind, placebo-controlled, multiple-ascending-dose trial of inclisiran administered as a subcutaneous injection in patients at high risk for ...

Novartis AG NVS has announced encouraging results from a prespecified analysis of pooled data from three phase III studies evaluating the safety and efficacy of inclisiran, its first-in-class ...

Overview “Inclisiran - Emerging Insight and Market Forecast – 2030” report outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed ...

In the V-MONO trial (ClinicalTrials.gov Identifier: NCT05763875), study participants were randomly assigned 2:1:1 to receive either inclisiran (n=174), ezetimibe (n=89) or placebo (n=87).

In this study, a total of 290 patients (Group 1) previously treated with inclisiran in ORION-1, received twice-a-year injections of inclisiran 300mg, with a follow up at day 210 (the primary ...

However, new competition emerged with The Medicines Company and its CEO, Dr. Clive Meanwell. The Medicines Company was developing a drug called inclisiran that represented a whole new approach to ...

Inclisiran lowers low-density lipoprotein (LDL; 'bad') cholesterol for up to one year in patients with high cardiovascular risk and elevated LDL cholesterol.

In this phase 3, double-blind trial, we randomly assigned, in a 1:1 ratio, 482 adults who had heterozygous familial hypercholesterolemia to receive subcutaneous injections of inclisiran sodium (at ...

In total, 3,576 patients were treated with inclisiran and 1,968 with placebo (mean age 64 years; 33% female in both groups). For those who received inclisiran, 72.2% were treated for more than 2 but ...

1.3 These recommendations are not intended to affect treatment with inclisiran that was started in the NHS before this guidance was published. People having treatment outside these recommendations may ...